Navigation Links
Transcept Pharmaceuticals to Present at 11th Annual BIO CEO & Investor Conference
Date:2/5/2009

ents for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to Intermezzo being the first commercially available sleep aid in its target indication. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, or unexpected expenses incurred in connection with, obtaining regulatory approval , market acceptance and commercialization of Intermezzo(R).

     Contacts:

     Transcept Pharmaceuticals, Inc.
     Michael Gill
     Director of Communications
     (510) 215-3575
     mgill@transcept.com

     The Ruth Group
     Investors / Media
     Stephanie Carrington / Jason Rando
     (646) 536-7017 / 7025
     scarrington@theruthgroup.com
     jrando@theruthgroup.com

'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
2. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
3. Transcept Pharmaceuticals Appoints Key Senior Executives
4. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
7. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
8. Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009
9. XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
10. XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
11. Indevus Pharmaceuticals Announces Release of 2008 Annual Report

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...AGO, Nov. 30 Dr. Jessica Torrente,...gton University Medical Center in Washington, D.C....pecific Gamma Imaging (BSGI) in clinical practice ...f breast cancer today at the annual meeting of the..., "The purpose of the exhibit was to demonstrate ...
(Date:11/30/2009)..., SEATTLE, Nov. 30 Cell...nnounced today that its new class of platinum-base...onstrated a stronger anti-tumor potency and activi...compounds as well as the ability to overcome cispl... were presented in a paper titled "Novel Bis-plati...
(Date:11/29/2009)... is available in German . , The concept of ...physics. The most famous example is that of quarks... Now Prof. Bella Lake from Helmholtz-Zentrum Berli...s report for the first time an experimental realiz...ed in a condensed matter system. , The concept o...
(Date:11/26/2009)...YETTE, Ind. - A new generation of ultrasmall trans... structures called semiconducting nanowires are cl...rs at IBM, Purdue University and the University of...ve learned how to create nanowires with layers of ...e atomic level, which is a critical requirement fo...
Breaking Biology Technology:Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3Spinons -- confined like quarks 2Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3
... second in a series of articles on developing star...realm. The first edition of Early Stage focused ...adison, Wis. - So now that you know you have a pa... either one of which could be branded, what,s next...iscuss how you pick your business name. In today,s...
...an elevator next to a venture capitalist who could... the first thing about it yet. , ,You have 90 sec...se of the Elevator Pitch Olympics, a yearly event ...r, a panel of eight investors dished out advice an...resented their businesses in front of an audience....
...are signs the United States economy is cooling off... the third quarter is not one of them, according t...ists invested $6.2 billion in 797 deals during the... in both categories, according to a MoneyTree Rep... Venture Capital Association based on data from ...
Other Biology Technology:Early Stage Step 2: Choosing a domain name 2Early Stage Step 2: Choosing a domain name 3Early Stage Step 2: Choosing a domain name 49 tips for making 90 seconds count in an investment pitch 2Venture capital above $6B for third straight quarter 2Venture capital above $6B for third straight quarter 3
(Date:11/26/2009)...rized for their impressive antlers, red deer have .... But a deer,s antlers are much more than decorati...her when duelling. John Currey, from The Universit...l properties of bone for over half a century and h...of antler through a long-standing collaboration wi...
(Date:11/26/2009)... survey carried out in eight European countries ha...fectious disease pandemic could have a significant...s writing in the open access journal BMC Infectio...on school days and weekends/holidays, finding that... Hens, from Hasselt and Antwerp University, Belgiu...
(Date:11/26/2009)..., Heidelberg, 27 November 2009 What are the bare... required to produce a cell that can survive on it...cell, and understand how an entire organism functi...ons that scientists in a partnership between the E...delberg, Germany, and the Centre de Regulacio Genm...
Breaking Biology News(10 mins):Tough yet stiff deer antler is materials scientist's dream 2School closure could reduce swine flu transmission by 21 percent 2First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Couples Dash Around Manhattan in Search of a Diamond 26 More While Raising Money for The Leukemia 26 Lymphoma Society 57204 1Couples Dash Around Manhattan in Search of a Diamond 26 More While Raising Money for The Leukemia 26 Lymphoma Society 57204 2Couples Dash Around Manhattan in Search of a Diamond 26 More While Raising Money for The Leukemia 26 Lymphoma Society 57204 3Neuronascent to Present at Life Sciences Summit 2009 14061 1Neuronascent to Present at Life Sciences Summit 2009 14061 2Mars Veterinary Offers New Insights Into Mixed Breed Dogs 57197 1Mars Veterinary Offers New Insights Into Mixed Breed Dogs 57197 2Mars Veterinary Offers New Insights Into Mixed Breed Dogs 57197 3
...ators at the University of Rochester Medical Cente...ers a ray of hope for children with Batten disease...emingly healthy kids, progressively robs them of t...tely kills them in their young twenties. , The st...ental Neurology, explains how investigators improv...
...TOWN, Mass., Dec. 12, 2007 -- The National Science...on Gladden 1859 Professor of Biology, and Dwight W...College, a grant in the amount of $105,110. The gr... at Williams College for the study of ultra fast b...sciences. , The project builds on research transf...
... processes, such as when to multiply, are often re... timing of interactions between proteins. North Ca... the way in which a specific protein-protein inter...witches off, leading to uncontrolled cell prolifer...er published in the December 2007 edition of the C...
Other Biology News:Research unveils new hope for deadly childhood disease 2NSF awards Williams funding for high-speed imaging faciltity 2Why the switch stays on 2Why the switch stays on 3
Rabbit Anti-Human SNAPAP Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
HiTrap NHS-activated HP from GE Healthcare, formerly Amersham Biosciences
Goat Anti-Human Serpin A8 Polyclonal Antibody, Unconjugated from R&D Systems
Goat Anti-Human CXCL14 / BRAK Polyclonal Antibody, Unconjugated from R&D Systems
Biology Products: